Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Harvey RD. Clin Pharmacol. 2014 May 8;6:87-96. eCollection 2014. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Bringhen S et al. Blood. 2014 May 22. pii: blood-2014-03-563759. [Epub ahead of…
Updates to the guidelines for the diagnosis and management of multiple myeloma. Pratt G et al. Br J Haematol. 2014 May 7. doi: 10.1111/bjh.12926. [Epub ahead of print]. Multiple myeloma: advances reported in 2013 are useful in the clinic. Anderson K. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):808-11. Role of new drugs incorporated into…
Clinical benefits of femoroplasty: a nonsurgical alternative for the management of femoral metastases. Plancarte R et al. Pain Physician. 2014 May-Jun;17(3):227-34. Comparative Effectiveness on Survival of Zoledronic Acid versus Pamidronate in Multiple Myeloma. Sanfilippo K et al. Leuk Lymphoma. 2014 May 21:1-22. [Epub ahead of print]. Aprepitant for the control of delayed nausea and vomiting…
Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Greenfield DM et al. Bone Marrow Transplant. 2014 May 19. doi: 10.1038/bmt.2014.103. [Epub ahead of print]. Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture: a clinical perspective. Bours…
Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Leiba M et al. Br J Haematol. 2014 May 26. doi: 10.1111/bjh.12946. [Epub ahead of print]. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for newly diagnosed myeloma multiple patients. Blanes M…
The British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) Guideline for the Diagnosis and Management of Myeloma has recently been updated. Originally published in 2011, the latest changes to the guideline include the following recommendations: cytogenetic analysis should be performed in all patients at diagnosis; a second autologous stem…
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. Rabin N et al. Int J Lab Hematol. 2014 Mar 27. doi: 10.1111/ijlh.12205. [Epub ahead of print]. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow…
Advances in supportive care for multiple myeloma.Raje NS et al. J Natl Compr Canc Netw. 2014 Apr 1;12(4):502-11.Surgical management of primary tumors of the cervical spine: surgical considerations and avoidance of complications.Kaloostian PE et al. Neurol Res. 2014 Apr 10:1743132814Y0000000367. [Epub ahead of print].Post-operative Cement Augmentation after 360-degree Fusion for Highly Unstable Vertebral Fractures in…
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Jackson GH et al. Br J Haematol. 2014 Mar 27. doi: 10.1111/bjh.12861. [Epub ahead of print]. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine. Wanchoo R et al. J Oncol Pharm Pract. 2014…
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.Mateos MV et al. Haematologica. 2014 Apr 24. [Epub ahead of print].Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.Ahn SY et…